Trial Profile
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects with moderate to severe plaque psoriasis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2011
Price :
$35
*
At a glance
- Drugs Onercept (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Serono
- 26 Jul 2011 New trial record